Metastatic insulinomas are rare malignant neuroendocrine tumours characterised by inappropriate insulin secretion, resulting in life-threatening hypoglycaemia. Data from a recent study showed that peptide receptor radionuclide therapy (PRRT) is effective in controlling the symptoms of patients with metastatic insulinomas. In the largest study to date focused on PRRT-treated metastatic insulinomas, it was shown that more than 80% of patients with malignant insulinomas experienced an improvement in the hypoglycaemic episodes, and 60% were able to reduce the use of other anti-hypoglycaemic drugs. These findings indicate that PRRT should be considered at an earlier point, as first or second-line therapy, in the management algorithm of patients with symptomatic malignant insulinomas.
Read the full article in the Journal of Nuclear Medicine.
16/02/2024